PWR-FAST
CompletedPhase NAPreventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways)
Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways): A Randomized, Placebo-Controlled, Double-Blind Clinical Trial
Lead sponsor
Asset
Semaglutide
GLP-1 agonist
Listed sites
1
Recruiting sites
-
Actual enrollment
160
Study population
Obesity / overweight
Eligibility highlights
-
Primary endpoint
•Body weight, % change
Registered trial locations
Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Who this study enrolls
Who can enroll
Inclusion criteria
Exclusion criteria
Endpoints (15)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Weight & body composition
6 endpointsPercentage of weight regain from baseline
Time frame:180 days
Body weight, % change
percent change from baseline, improvement
BMI changes
Time frame:180 days
BMI, change
change from baseline, improvement
Visceral fat rating change from baseline
Time frame:180 days
Visceral fat, change
change from baseline, improvement
fat-free mass changes
Time frame:180 days
Lean mass
change from baseline, improvement
visceral fat changes
Time frame:180 days
Visceral fat, change
change from baseline, improvement
total body water changes
Time frame:180 days
change from baseline, improvement
Glycemic / diabetes
2 endpointsblood glucose levels change
Time frame:180 days
change from baseline, improvement
blood HbA1c change
Time frame:180 days
HbA1c, change
change from baseline, improvement
LOINC 4548-4
Cardiometabolic biomarkers
4 endpointsblood total cholesterol change
Time frame:180 days
Total cholesterol, change
change from baseline, improvement
LOINC 2093-3
blood LDL change
Time frame:180 days
LDL-C, change
change from baseline, improvement
LOINC 13457-7
blood triglycerides change
Time frame:180 days
Triglycerides, change
change from baseline, improvement
LOINC 2571-8
Systolic and diastolic blood pressure change
Time frame:180 days
change from baseline, improvement
Patient-reported / QoL
3 endpointsEffect of glucomannan, inulin, and psyllium on appetite assessed using mean postprandial participant-reported visual analog score (VAS) ratings from 0 to 10 points, where 0 is appetite absence and 10 good appetite, following a standardized breakfast
Time frame:180 days
descriptive, improvement
Fasting and mean postprandial changes in visual analog score (VAS) ratings from 0 to 10 points for thirst, nausea, and well-being following a standardized breakfast.
Time frame:180 days
PGI, change
change from baseline, improvement
componentsthirst vas, nausea vas, well being vas
Participant-reported control of eating evaluated using the Control of Eating Questionnaire (CoEQ) with 20 questions containing 5 oprions where 1 means the best and 5 the worst outcome
Time frame:180 days
descriptive, improvement
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.